Thomas T Chen

US Patent:

6358916, Mar 19, 2002

Filed:

Jul 22, 1998

Appl. No.:

09/120818

Inventors:

Thomas T. Chen - Storrs CT 06268
Maria J. M. Chen - Storrs CT 06268
Xiuchun Tian - Storrs CT 06268-1505

International Classification:

A61K 3830

US Classification:

514 2, 530351, 530399, 536 235

Abstract:

Methods of increasing mitosis in cells; of increasing cell attachment in culture; of enhancing wound healing; and of inhibiting proliferation of malignant cells, are described, comprising administering an E domain peptide from insulin-like growth factor I (IGF-I) of a trout, or administering an E domain peptide homolog, an E domain peptide fusion protein, or a nucleic acid encoding an E domain peptide, an E domain peptide homolog or an E domain peptide fusion protein.

US Patent:

6610302, Aug 26, 2003

Filed:

Sep 26, 2000

Appl. No.:

09/669642

Inventors:

Thomas T. Chen - Storrs CT
Maria J. M. Chen - Storrs CT

Assignee:

University of Connecticut - Storrs CT

International Classification:

A61K 3900

US Classification:

4241981, 514 12, 530399

Abstract:

Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.

US Patent:

7118752, Oct 10, 2006

Filed:

Mar 18, 2002

Appl. No.:

10/100492

Inventors:

Thomas T. Chen - Storrs CT, US
Maria J. M. Chen - Storrs CT, US
Ya-Huei Kuo - Worcester MA, US

Assignee:

University of Connecticut - Farmington CT

International Classification:

A61K 39/00
C07K 14/475

US Classification:

4241921, 4241981, 530351, 530399, 514 12, 526 235, 4353201, 435325, 435 695, 435 697

Abstract:

A method is described for using an a-type or b-type E domain of the human or trout IGF peptide for the inhibition of proliferation and invasiveness of a broad spectrum of malignant cells and for the inhibition of angiogenesis. The peptide species can be a homologue of the E-domain of IGF-1 or a fusion protein comprising the E-domain of IGF-1. It can be administered to one or more malignant cells in a pharmaceutically acceptable composition, or alternatively, can be administered to one or more malignant cells by transforming the cells with exogenous nucleic acid that results in the expression of the E domain of IGF-1 in the cell.

US Patent:

7250169, Jul 31, 2007

Filed:

Aug 25, 2003

Appl. No.:

10/647732

Inventors:

Thomas T. Chen - Storrs CT, US
Maria J. M. Chen - Storrs CT, US

Assignee:

University of Connecticut - Farmington CT

International Classification:

A61K 39/00

US Classification:

4241921, 4241981, 514 12, 530399, 530351, 536 235, 4353201, 435 695, 435 697

Abstract:

Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.

US Patent:

7655462, Feb 2, 2010

Filed:

May 2, 2007

Appl. No.:

11/799623

Inventors:

Thomas T. Chen - Storrs CT, US
Maria J. M. Chen - Storrs CT, US

Assignee:

E-P Therapeutics, Inc. - Ridgefield CT

International Classification:

C12N 5/00
C12N 5/02
C12Q 1/68
A01N 43/04
A61K 31/70

US Classification:

435375, 435384, 435 6, 514 44

Abstract:

Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.

US Patent:

7700353, Apr 20, 2010

Filed:

Feb 15, 2006

Appl. No.:

11/354484

Inventors:

Thomas T. Chen - Storrs CT, US
Maria J. M. Chen - Storrs CT, US

Assignee:

E-P Therapeutics, Inc. - Ridgefield CT

International Classification:

C12N 5/00
C07K 14/65
A61K 38/30

US Classification:

435375, 435325, 435366, 530303, 530399, 514 2, 514 3

Abstract:

A method is described for using an E-domain peptide for the induction of apoptosis in a cancer cells. In particular, the invention relates to methods for using a-type E-domain peptide from trout IGF and/or a b-type E-domain peptide from human IGF for the induction of apoptosis in a broad spectrum of cancer cells. The peptide species can be a homologue of the E-domain of IGF-1 or a fusion protein comprising the E-domain of IGF-1. It can be administered to one or more cancer cells alone or in a pharmaceutically acceptable composition.

US Patent:

20090221072, Sep 3, 2009

Filed:

May 13, 2009

Appl. No.:

12/465053

Inventors:

Thomas T. Chen - Storrs CT, US
Maria J.M. Chen - Storrs CT, US

International Classification:

C12N 5/06

US Classification:

435377, 435325

Abstract:

Compositions and methods are described for using the Ea4-peptide of pro-IGF-I or human Eb-peptide of pro-IGF-I to inhibit hematopoiesis and to induce differentiation of neuroblastoma cells and neuronal stem cells.

US Patent:

20090318355, Dec 24, 2009

Filed:

May 13, 2009

Appl. No.:

12/465065

Inventors:

Thomas T. Chen - Storrs CT, US
Maria J.M. Chen - Storrs CT, US

International Classification:

A61K 38/18
A61P 17/02

US Classification:

514 12

Abstract:

A method is described for using the Ea4-peptide of pro-IGF-I or human Eb-peptide of pro-IGF-I for enhancing the proliferation of fibroblasts and closure of wound. The peptide species can be homologous of trout Ea4-peptide, human Eb-peptide of pro-IGF-I or a fusion protein comprising the Ea4- or Eb-peptide of pro-IGF-I. It can be administered any wound in a pharmaceutically acceptable composition alone or in combination with other compounds.